Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 66.7% in June

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 6,000 shares, a growth of 66.7% from the May 31st total of 3,600 shares. Based on an average daily trading volume, of 128,100 shares, the short-interest ratio is presently 0.0 days.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS CHGCY traded down $0.32 during mid-day trading on Friday, reaching $17.77. The company’s stock had a trading volume of 170,764 shares, compared to its average volume of 68,626. The stock has a 50-day moving average of $15.89 and a two-hundred day moving average of $17.89. The stock has a market capitalization of $58.46 billion, a P/E ratio of 26.13 and a beta of 0.82. Chugai Pharmaceutical has a 1-year low of $13.26 and a 1-year high of $22.61.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Wednesday, April 24th. The company reported $0.15 EPS for the quarter. The business had revenue of $1.60 billion during the quarter. Chugai Pharmaceutical had a net margin of 31.49% and a return on equity of 20.44%. Analysts predict that Chugai Pharmaceutical will post 0.7 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.